Total Payments
$2,896
2024 Payments
$116.15
Companies
32
Transactions
102
Medicare Patients
2,986
Medicare Billing
$336,775
Payment Breakdown by Category
Food & Beverage$2,281 (78.7%)
Other$366.06 (12.6%)
Education$249.70 (8.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,281 | 94 | 78.7% |
| Long term medical supply or device loan | $366.06 | 4 | 12.6% |
| Education | $249.70 | 4 | 8.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $767.44 | 13 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $376.72 | 5 | $0 (2023) |
| PFIZER INC. | $218.79 | 12 | $0 (2022) |
| Lilly USA, LLC | $192.00 | 6 | $0 (2022) |
| Astellas Pharma US Inc | $182.02 | 6 | $0 (2021) |
| EISAI INC. | $108.42 | 6 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $102.59 | 5 | $0 (2021) |
| Amgen Inc. | $94.35 | 5 | $0 (2022) |
| Gilead Sciences, Inc. | $82.43 | 5 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $75.22 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $116.15 | 1 | Janssen Biotech, Inc. ($116.15) |
| 2023 | $690.56 | 9 | Janssen Biotech, Inc. ($486.69) |
| 2022 | $1,003 | 39 | Novartis Pharmaceuticals Corporation ($210.06) |
| 2021 | $828.88 | 38 | Astellas Pharma US Inc ($182.02) |
| 2020 | $20.78 | 1 | Incyte Corporation ($20.78) |
| 2019 | $52.72 | 2 | TerSera Therapeutics LLC ($52.72) |
| 2018 | $113.05 | 7 | Eisai Inc. ($47.63) |
| 2017 | $71.65 | 5 | Clovis Oncology, Inc. ($19.00) |
All Payment Transactions
102 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $116.15 | General |
| Category: Oncology | ||||||
| 10/05/2023 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $121.38 | General |
| Category: Oncology | ||||||
| 09/15/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: Oncology | ||||||
| 08/30/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: Oncology | ||||||
| 08/23/2023 | E.R. Squibb & Sons, L.L.C. | ABECMA (Biological) | Education | In-kind items and services | $37.21 | General |
| Category: Oncology | ||||||
| 08/17/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: Oncology | ||||||
| 03/01/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology | ||||||
| 03/01/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology | ||||||
| 02/15/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| 01/14/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| 09/29/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Oncology | ||||||
| 09/27/2022 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.12 | General |
| Category: Hematology/Oncology | ||||||
| 09/26/2022 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $27.14 | General |
| 09/23/2022 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $21.35 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/22/2022 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/20/2022 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: Oncology | ||||||
| 09/16/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: ONC | ||||||
| 09/12/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.26 | General |
| Category: Oncology | ||||||
| 09/07/2022 | Sobi, Inc | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/06/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Oncology | ||||||
| 09/02/2022 | PFIZER INC. | XALKORI (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: ONCOLOGY | ||||||
| 08/31/2022 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2022 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $26.11 | General |
| Category: IMMUNOLOGY | ||||||
| 08/29/2022 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | Cash or cash equivalent | $19.35 | General |
| Category: Hematology | ||||||
| 08/24/2022 | GENZYME CORPORATION | ELITEK (Biological), SARCLISA | Food and Beverage | In-kind items and services | $31.94 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 1,008 | 2,469 | $318,114 | $81,415 |
| 2022 | 40 | 1,475 | 30,893 | $586,713 | $158,350 |
| 2021 | 7 | 198 | 471 | $49,760 | $24,824 |
| 2020 | 6 | 305 | 607 | $144,888 | $72,186 |
Total Patients
2,986
Total Services
34,440
Medicare Billing
$336,775
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 19 | 143 | $149,149 | $18,129 | 12.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 106 | 166 | $36,354 | $15,739 | 43.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 78 | $23,010 | $10,500 | 45.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 19 | 91 | $29,575 | $9,272 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 51 | 51 | $21,420 | $7,455 | 34.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 125 | 319 | $3,190 | $2,680 | 84.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 36 | 40 | $6,000 | $2,637 | 43.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 100 | 225 | $6,525 | $2,318 | 35.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 115 | 290 | $6,380 | $2,199 | 34.5% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 30 | 51 | $3,621 | $1,290 | 35.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 19 | 50 | $4,300 | $1,270 | 29.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 13 | 51 | $4,080 | $1,112 | 27.3% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 33 | 58 | $2,958 | $1,045 | 35.3% |
| 82306 | Vitamin d-3 level | Office | 2023 | 31 | 36 | $2,700 | $1,044 | 38.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 11 | 21 | $3,045 | $1,007 | 33.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 24 | 65 | $3,510 | $655.21 | 18.7% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 22 | 32 | $1,536 | $526.72 | 34.3% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 26 | 39 | $1,482 | $521.04 | 35.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 13 | 30 | $1,530 | $364.20 | 23.8% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 21 | 23 | $966.00 | $339.94 | 35.2% |
| 83550 | Iron binding capacity | Office | 2023 | 26 | 37 | $888.00 | $317.09 | 35.7% |
| 87389 | Detection test by immunoassay technique for hiv-1 antigen and hiv-1 and hiv-2 antibodies | Office | 2023 | 11 | 11 | $748.00 | $259.60 | 34.7% |
| 83540 | Iron level | Office | 2023 | 26 | 37 | $666.00 | $234.58 | 35.2% |
| 82746 | Folic acid level, serum | Office | 2023 | 12 | 12 | $492.00 | $172.92 | 35.1% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 19 | 20 | $340.00 | $118.40 | 34.8% |
About Dr. Sobia Nabeel, M.D
Dr. Sobia Nabeel, M.D is a Hematology & Oncology healthcare provider based in Arlington, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2009. The National Provider Identifier (NPI) number assigned to this provider is 1306088950.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sobia Nabeel, M.D has received a total of $2,896 in payments from pharmaceutical and medical device companies, with $116.15 received in 2024. These payments were reported across 102 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($2,281).
As a Medicare-enrolled provider, Nabeel has provided services to 2,986 Medicare beneficiaries, totaling 34,440 services with total Medicare billing of $336,775. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Arlington, TX
- Active Since 03/28/2009
- Last Updated 09/11/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1306088950
Products in Payments
- ERLEADA (Drug) $544.35
- KISQALI (Drug) $210.06
- RYBREVANT (Drug) $121.38
- KEYTRUDA (Biological) $83.35
- Lenvima (Drug) $77.44
- PADCEV (Drug) $76.43
- VERZENIO (Drug) $76.42
- IMBRUVICA (Drug) $74.57
- XTANDI (Drug) $70.56
- Trodelvy (Drug) $70.51
- IBRANCE (Drug) $64.26
- XALKORI (Drug) $63.96
- ZOLADEX (Drug) $52.72
- Tavalisse (Drug) $51.68
- BOSULIF (Drug) $40.61
- Kyprolis (Drug) $39.34
- NERLYNX (Drug) $39.08
- JAKAFI (Drug) $38.90
- OPDIVO (Biological) $38.01
- ABECMA (Biological) $37.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Arlington
Neelima Denduluri, M.d, M.D
Hematology & Oncology — Payments: $95,053
Hematology & Oncology $95,053
Keeran Sampat, Md, MD
Hematology & Oncology — Payments: $22,287
Hematology & Oncology $22,287
Revathi Angitapalli, M.d, M.D
Hematology & Oncology — Payments: $20,808
Hematology & Oncology $20,808
John Adams, Do, DO
Hematology & Oncology — Payments: $16,414
Hematology & Oncology $16,414
Karel Dicke, Md Phd, MD PHD
Hematology & Oncology — Payments: $3,885
Hematology & Oncology $3,885
Anwar Khurshid, Md, MD
Hematology & Oncology — Payments: $3,690
Hematology & Oncology $3,690